|
Jul 1
|
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading
|
|
Jun 29
|
Autolus Therapeutics (AUTL) Presents Positive Long-Term Obe-cel Data at EHA 2025
|
|
Jun 20
|
Syncona Ltd (LSE:SYNC) Full Year 2025 Earnings Call Highlights: Navigating Market Challenges ...
|
|
Jun 17
|
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
|
|
Jun 12
|
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
|
|
Apr 16
|
April 2025's Top Penny Stocks To Watch
|
|
Dec 30
|
Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?
|
|
Oct 17
|
Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy
|
|
Oct 16
|
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
|
|
Oct 16
|
Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts
|
|
Oct 9
|
Autolus Therapeutics PLC (AUTL) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
|
Jul 26
|
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
|
|
May 31
|
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
|
|
May 18
|
Q1 2024 Autolus Therapeutics PLC Earnings Call
|
|
May 17
|
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
|
|
May 14
|
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
|
|
May 13
|
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
|
|
Apr 25
|
Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year
|
|
Apr 24
|
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
|
|
Apr 23
|
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
|